Biotech Values

[DewDiligence]

Added EGRX today for the same reason—playing a hunch about a deal with MDCO on Angiomax (#msg-113377784). Still a relatively small position.

It’s annoying to buy a stock after it has tripled (since the Trenda settlement with Teva in February: #msg-110943484), but sometimes it’s the right decision. If EGRX inks a deal with MDCO for its ready-to-infuse formulation of Angiomax, the share price is certainly going higher.